Acquired von Willebrand syndrome (AvWS) is managed with a protocol focused on preventing and controlling bleeding. The approach below outlines the first-line strategy; the complete decision sequence is available via the link below.
First-line therapy includes desmopressin (DDAVP), a synthetic analogue of vasopressin, used to help prevent and control bleeding. Antifibrinolytic therapy may be considered as an adjunct, or — in certain presentations — as a standalone measure. The complete regimen, including specific agents, decision criteria, and the full clinical algorithm, is available in the structured protocol.
DOI: 10.5603/ahp.107038